首页> 外文OA文献 >Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

【2h】

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

机译：尼古鲁单抗（抗PD-1，BMS-936558，ONO-4538）单药或与伊匹单抗联合治疗的晚期黑色素瘤患者的外周和肿瘤免疫相关性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Michael A Postow; Diana M Cardona; Janis M Taube; Robert A Anders; Clive R Taylor; Jedd D Wolchok; Margaret K Callahan; Michael A Curran; Alexander M Lesokhin; Joseph F Grosso; Christine E Horak; John Cogswell; Jason S Simon; Ashok K Gupta; Mario Sznol;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab [J] . Michael A Postow, Diana M Cardona, Janis M Taube, Journal of Translational Medicine . 2014,第SUPPLEMENTa1期

机译：尼古鲁单抗（抗PD-1，BMS-936558，ONO-4538）单药或与伊匹单抗联合治疗的晚期黑色素瘤患者的外周和肿瘤免疫相关性
2. Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab [J] . Margaret K Callahan, Christine E Horak, Michael A Curran, Journal for ImmunoTherapy of Cancer . 2013,第S1期

机译：尼古鲁单抗（抗PD-1，BMS-936558，ONO-4538）和伊匹单抗联合治疗的晚期黑色素瘤患者的外周血和肿瘤生物标志物
3. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy [J] . Rizvi N. A., Antonia S. J., Shepherd F. A., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Nivolumab（Anti-PD-1; BMS-936558，ONO-4538）单一治疗或与贝伐单抗（BEV）联合用于先前用化学疗法治疗的非小细胞肺癌（NSCLC）的维持
4. Results of treatment of patients with stomach cancer advanced form treated by combination of lw level laser therapy (LLLT) and other methods (10-years experience) [C] . V.A.Mikhailov Conference on Laser Florence'99: A Window on the Laser Medicine World 28-31 October 1999 Florence, Italy . 1999

机译：低水平激光疗法（LLLT）和其他方法相结合治疗晚期胃癌患者的结果（10年经验）
5. Effective combination of syngeneic HCT with CRCL vaccination to treat BCR-ABL+ leukemia, and, CD4+CD25+FOXP3+ regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. [D] . Chen, Xinchun. 2006

机译：同基因HCT与CRCL疫苗的有效结合可治疗BCR-ABL +白血病，CD4 + CD25 + FOXP3 +调节性T细胞可抑制活动性疾病患者的结核分枝杆菌免疫力。
6. Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1 BMS-936558 ONO-4538) monotherapy or in combination with ipilimumab [O] . Michael A Postow, Diana M Cardona, Janis M Taube, 2014

机译：尼古鲁单抗（抗PD-1BMS-936558ONO-4538）单药或与伊匹单抗联合治疗的晚期黑色素瘤患者的外周和肿瘤免疫相关性
7. Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab [O] . 2013

机译：尼古鲁单抗（抗PD-1，BMS-936558，ONO-4538）和伊匹单抗联合治疗的晚期黑色素瘤患者的外周血和肿瘤生物标志物

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

著录项

相似文献

相关主题

期刊订阅